Bayer's new CEO says nothing is off the table when it comes to assessing the future direction of the business. As part of a company-wide strategic review, he and his executive team will decide whether to break up or keep in place Bayer's three pillar structure, comprising Consumer Health, Pharmaceuticals and Crop Science.
Bayer could be the next in line to spin-off its Consumer Health business. Kicking off a company-wide strategic review, new CEO Bill Anderson has promised investors that “nothing is off the table.”
Speaking as the German firm reported its Q2 results, Anderson – who took the helm on 1 June – said...